🇺🇸 Sandostatin LAR in United States

FDA authorised Sandostatin LAR on 25 November 1998 · 24,839 US adverse-event reports

Marketing authorisation

FDA — authorised 25 November 1998

  • Application: NDA021008
  • Marketing authorisation holder: NOVARTIS
  • Status: supplemented

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 4,138 reports (16.66%)
  2. Diarrhoea — 3,329 reports (13.4%)
  3. Fatigue — 2,546 reports (10.25%)
  4. Malaise — 2,452 reports (9.87%)
  5. Needle Issue — 2,334 reports (9.4%)
  6. Blood Pressure Increased — 2,198 reports (8.85%)
  7. Pain — 2,022 reports (8.14%)
  8. Nausea — 2,008 reports (8.08%)
  9. Asthenia — 1,935 reports (7.79%)
  10. Malignant Neoplasm Progression — 1,877 reports (7.56%)

Source database →

Other Endocrinology / Oncology approved in United States

Frequently asked questions

Is Sandostatin LAR approved in United States?

Yes. FDA authorised it on 25 November 1998.

Who is the marketing authorisation holder for Sandostatin LAR in United States?

NOVARTIS holds the US marketing authorisation.